U.S. Markets closed

Eisai Co., Ltd. (ESALY)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
54.02+0.44 (+0.82%)
At close: 3:45PM EDT
People also watch
TKPYYKCRPYALPMYMSBHYDNZOY

Eisai Co., Ltd.

4-6-10, Koishikawa
Bunkyo-ku
Tokyo 112-8088
Japan
81 3 3817 3016
http://www.eisai.co.jp

Sector
Industry
Full Time Employees10,452

Key Executives

NameTitlePayExercisedAge
Mr. Haruo NaitoChief Exec. Officer, Representative Corp. Officer and Director1.17MN/A70
Gary HendlerChief Commercial Officer-Oncology Bus., SVP, Pres-EMEA & Eisai Global Oncology Bus.987.23kN/A51
Dr. Lynn D. Kramer M.D., FAANChief Clinical Officer & Chief Medical Officer of Neurology Bus. Group and VP1.06MN/A67
Mr. Alexander ScottVP and Chief Strategy Officer & Head of Strategy Dept - Neurology Bus. Group640.37kN/AN/A
Ms. Shaji ProcidaVP, Pres of Eisai Inc and Chief Operating Officer of Eisai Inc853.82kN/A46
Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals worldwide. The company offers Halaven and Lenvima, an anticancer agent; Aloxi, an antiemetic agent; Aricept, a treatment for Alzheimer’s disease; Fycompa, an antiepileptic agent; Methycobal for peripheral neuropathy treatment; BELVIQ for anti-obesity treatment; and LYRICA for neuropathic pain treatment. It also provides Lunesta, a non-benzodiazepine hypnotic agent for insomnia treatment; Pariet, a proton pump inhibitor; HUMIRA, a human anti-TNF-a monoclonal antibody; and epilepsy franchise products, including Zonegran, Zebinix, Fycompa, and Inovelo, which are antiepileptic agents. In addition, the company offers Inovelon/BANZEL for the treatment of Lennox-Gastaut syndrome; Actonel, an osteoporosis treatment; and Stronger Neo-Minophagen C/Glycyron tablets for liver disease/allergic disease treatment. It has strategic partnerships with Quintiles Inc. for developing six types of anticancer compound candidates; and Epizyme, Inc. to discover, develop, and commercialize therapeutics targeting EZH2, an epigenetic enzyme, for the treatment of lymphoma and other cancers in genetically defined patients. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was founded in 1941 and is headquartered in Tokyo, Japan.

Corporate Governance

Eisai Co., Ltd.’s ISS Governance QualityScore as of July 1, 2017 is 3. The pillar scores are Audit: 1; Board: 1; Shareholder Rights: 10; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.